These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25304949)

  • 1. Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer.
    Dzhugashvili M; Luengo-Gil G; García T; González-Conejero R; Conesa-Zamora P; Escolar PP; Calvo F; Vicente V; Ayala de la Peña F
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):595-602. PubMed ID: 25304949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
    Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant.
    Schirmer MA; Mergler CP; Rave-Fränk M; Herrmann MK; Hennies S; Gaedcke J; Conradi LC; Jo P; Beissbarth T; Hess CF; Becker H; Ghadimi M; Brockmöller J; Christiansen H; Wolff HA
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):149-57. PubMed ID: 22000747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Arrazubi V; Suárez J; Guerrero D; Gómez M; Viúdez A; Arias F; Balén E; Vera R
    Colorectal Dis; 2013 Apr; 15(4):428-35. PubMed ID: 22958523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
    Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
    Terrazzino S; Agostini M; Pucciarelli S; Pasetto LM; Friso ML; Ambrosi A; Lisi V; Leon A; Lise M; Nitti D
    Pharmacogenet Genomics; 2006 Nov; 16(11):817-24. PubMed ID: 17047490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer.
    Nelson B; Carter JV; Eichenberger MR; Netz U; Galandiuk S
    Surgery; 2016 Nov; 160(5):1326-1332. PubMed ID: 27423551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04-01).
    Lee JH; Kim DY; Nam TK; Yoon SC; Lee DS; Park JW; Oh JH; Chang HJ; Yoon MS; Jeong JU; Jang HS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):955-61. PubMed ID: 22537540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
    Hur H; Kang J; Kim NK; Min BS; Lee KY; Shin SJ; Keum KC; Choi J; Kim H; Choi SH; Lee MY
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):669-76. PubMed ID: 20932673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis.
    Shin US; Yu CS; Kim JH; Kim TW; Lim SB; Yoon SN; Yoon YS; Kim CW; Kim JC
    Ann Surg Oncol; 2011 Aug; 18(8):2232-9. PubMed ID: 21347780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer.
    Yu CS; Kim TW; Kim JH; Choi WS; Kim HC; Chang HM; Ryu MH; Jang SJ; Ahn SD; Lee SW; Shin SS; Choi EK; Kim JC
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1020-6. PubMed ID: 17197127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel single-nucleotide polymorphism markers predictive of pathologic response to preoperative chemoradiation therapy in rectal cancer patients.
    Kim JC; Ha YJ; Roh SA; Cho DH; Choi EY; Kim TW; Kim JH; Kang TW; Kim SY; Kim YS
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):350-7. PubMed ID: 23490283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
    Kim JG; Chae YS; Sohn SK; Moon JH; Ryoo HM; Bae SH; Kum Y; Jeon SW; Lim KH; Kang BM; Park IJ; Choi GS; Jun SH
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):953-60. PubMed ID: 19219602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5-fluorouracil for locally advanced rectal cancer.
    Lu JY; Xiao Y; Qiu HZ; Wu B; Lin GL; Xu L; Zhang GN; Hu K
    J Surg Oncol; 2013 Sep; 108(4):213-9. PubMed ID: 23913795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
    Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
    Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
    Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
    Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer.
    Aristu JJ; Arbea L; Rodriguez J; Hernández-Lizoain JL; Sola JJ; Moreno M; Azcona JD; Díaz-González JA; García-Foncillas JM; Martínez-Monge R
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):748-55. PubMed ID: 18164861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
    Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
    Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.